Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2019-08-15
Target enrollment:
Participant gender:
Summary
This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy
in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological
therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart
and this may stimulate the immune system and allow the chemotherapy to kill more tumor cells.